董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Donald Elsey | 男 | Director | 68 | 4.89万美元 | 未持股 | 2021-10-29 |
| William E. Rhodes, III | 男 | Chairman of the Board | 67 | 未披露 | 未持股 | 2021-10-29 |
| Mario Crovetto | 男 | Director | 68 | 未披露 | 未持股 | 2021-10-29 |
| Oliver Schacht | 男 | Chief Executive Officer, Acting Chief Financial Officer and Director | 51 | 未披露 | 未持股 | 2021-10-29 |
| Prabhavathi Fernandes | 女 | Director | 72 | 未披露 | 未持股 | 2021-10-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Oliver Schacht | 男 | Chief Executive Officer, Acting Chief Financial Officer and Director | 51 | 未披露 | 未持股 | 2021-10-29 |
| Johannes Bacher | 男 | Chief Operating Officer | 52 | 未披露 | 未持股 | 2021-10-29 |
董事简历
中英对照 | 中文 | 英文- R. Donald Elsey
-
R.Donald Elsey自2019年2月起担任董事会成员。Elsey先生是一位生物技术，生命科学和高科技行业的资深人士，在大型股和小型股公司的国际财务管理和运营方面拥有丰富的经验。他目前是LyraTherapeutics，Inc.的首席财务官、财务主管和秘书，分别自2019年8月、10月和10月起担任该职位。此前，他曾担任Senseonics，Inc.的首席财务官，他于2015年2月至2019年2月担任该职位。任职Senseonics公司之前，他曾担任Regado Biosciences Corporation的首席财务官。他也曾担任LifeCell Corporation（私人持有的再生医学公司）的首席财务官，以及Emergent BioSolutions公司（生物防御公司）的首席财务官。他也曾担任Bioveris Corporation、Igen，Inc.和PE Corporation Applera的高级财务职务。Elsey先生目前任职于Regenerx Biopharmaceuticals，Inc.的董事会和审计委员会，以及癌症支持社区的董事会和财务主管。他持有Michigan State University的经济学学士学位和金融工商管理硕士学位，是注册管理会计师。
R. Donald Elsey has served on our Board since February 2019. Mr. Elsey is a biotechnology, life sciences and high technology industries veteran with extensive experience in international financial management and operations with both large cap and small cap companies. He is currently the CFO, Treasurer and Secretary of Lyra Therapeutics, Inc., roles he has served since August, October and October of 2019 respectively. Previously, he served as CFO of Senseonics, Inc., a position he has held from February 2015 to February 2019. Prior to Senseonics, he was CFO of Regado Biosciences Corporation. He has also served as CFO of LifeCell Corporation, a privately held regenerative medicine company, and as chief financial officer of Emergent Biosolutions, a biodefense company. He also has held senior financial positions at BioVeris Corporation, Igen, Inc. and PE Corporation Applera. Mr. Elsey currently serves on the board of directors and audit committee for RegeneRx Biopharmaceuticals, Inc. and on the board of directors and treasurer for Cancer Support Community. He holds a B.A. degree in Economics and an M.B.A. in Finance from Michigan State University and is a Certified Management Accountant. - R.Donald Elsey自2019年2月起担任董事会成员。Elsey先生是一位生物技术，生命科学和高科技行业的资深人士，在大型股和小型股公司的国际财务管理和运营方面拥有丰富的经验。他目前是LyraTherapeutics，Inc.的首席财务官、财务主管和秘书，分别自2019年8月、10月和10月起担任该职位。此前，他曾担任Senseonics，Inc.的首席财务官，他于2015年2月至2019年2月担任该职位。任职Senseonics公司之前，他曾担任Regado Biosciences Corporation的首席财务官。他也曾担任LifeCell Corporation（私人持有的再生医学公司）的首席财务官，以及Emergent BioSolutions公司（生物防御公司）的首席财务官。他也曾担任Bioveris Corporation、Igen，Inc.和PE Corporation Applera的高级财务职务。Elsey先生目前任职于Regenerx Biopharmaceuticals，Inc.的董事会和审计委员会，以及癌症支持社区的董事会和财务主管。他持有Michigan State University的经济学学士学位和金融工商管理硕士学位，是注册管理会计师。
- R. Donald Elsey has served on our Board since February 2019. Mr. Elsey is a biotechnology, life sciences and high technology industries veteran with extensive experience in international financial management and operations with both large cap and small cap companies. He is currently the CFO, Treasurer and Secretary of Lyra Therapeutics, Inc., roles he has served since August, October and October of 2019 respectively. Previously, he served as CFO of Senseonics, Inc., a position he has held from February 2015 to February 2019. Prior to Senseonics, he was CFO of Regado Biosciences Corporation. He has also served as CFO of LifeCell Corporation, a privately held regenerative medicine company, and as chief financial officer of Emergent Biosolutions, a biodefense company. He also has held senior financial positions at BioVeris Corporation, Igen, Inc. and PE Corporation Applera. Mr. Elsey currently serves on the board of directors and audit committee for RegeneRx Biopharmaceuticals, Inc. and on the board of directors and treasurer for Cancer Support Community. He holds a B.A. degree in Economics and an M.B.A. in Finance from Michigan State University and is a Certified Management Accountant.
- William E. Rhodes, III
-
WilliamE.Rhodes，III自2020年4月起担任董事会成员。在此之前，Rhodes先生自Curetis N.V.于2015年首次公开募股以来一直担任其监事会主席，直到2020年4月1日。罗兹先生是一位梦百合执行官，在梦百合行业拥有30多年的经验。在碧迪医疗器械有限公司的14年职业生涯中（BD，1998年至2012年），Rhodes先生担任过多个高级领导职位，包括BD Biosciences的全球总裁（2009年至2011年），BD的收入超过10亿美元。他也曾担任BD公司的执行官，负责BD&8217；s公司的所有业务的公司战略和并购职能。此外，他还创立了BD Ventures，这是Becton，Dickinson and Co.的风险投资部门。任职Becton Dickinson公司之前，他曾担任强生公司和辉瑞公司公司的高级商业开发职务。Rhodes先生还曾担任The William-James Co.的总裁，并拥有超过20次成功的收购和资产剥离的记录。他曾担任Andor Technologies公司的董事（2013年至2014年），也曾任职Novocell公司、Conticare Medical公司、Vitagen公司、Cellector公司、加州梦百合研究所、Bio公司、圣何塞州立大学研究基金会和硅谷领导小组的董事会。他目前担任Third Day Advisors LLC（2013年以来）、Omega Group plc（2013年以来）、Paramit Corporation LLC（2014年以来）的董事，以及Cayuga Venture Fund的顾问委员会成员（2013年以来）。Rhodes先生在康奈尔大学（Cornell University）担任多个顾问职位，包括担任麦戈文生命科学家庭中心（McGovern Family Center for Life Sciences）的顾问委员会（2013年以来）和康奈尔大学（Cornell）的企业家精神（2015年以来）。他还被任命为康奈尔大学农业和生命科学学院院长&8217；s Council-2016，并担任康奈尔大学Blackstone Launchpad-2016的风险顾问，此外，他还是《临床和转化医学》杂志的编辑委员会成员。Rhodes先生拥有Seton Hall University国际商务硕士学位和Cornell University工商管理硕士学位。他创立了11项新颖外用药物的美国专利，并一直担任Cornell University、Seton Hall University和San Jose State University的生命科学、创新技术和并购创业讲师。
William E. Rhodes, III has served on our Board since April 2020. Prior to that, Mr. Rhodes served as the Chairman of the Supervisory Board of Curetis N.V. since its Initial Public Offering “IPO” in 2015 until April 1 2020. Mr. Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes held several senior leadership positions, including roles as Worldwide President of BD Biosciences (2009-2011), a greater than $1 billion revenue segment of BD. He was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition functions for all of BD’s businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The William-James Co. and has a track record of over 20 successful acquisitions and divestitures. He was director of Andor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen Inc., Cellector Inc. and the California Healthcare Institute, BIO, the San Jose State University Research Foundation and Silicon Valley Leadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), Omega Group plc (since 2013), Paramit Corporation LLC (since 2014), and as a member of the Advisory Board of Cayuga Venture Fund (since 2013). Mr. Rhodes has a number of advisory roles with Cornell University, including serving on the Advisory Councils of the McGovern Family Center for Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He also was appointed to the Cornell College of Agriculture and Life Sciences Dean’s Council -2016 and served as a Venture Consultant for Cornell’s Blackstone Launchpad -2016 Moreover, he is on the Editorial Board of the journal Clinical and Translational Medicine. Mr. Rhodes holds a Master’s degree in International Business from Seton Hall University and a BSc degree from Cornell University. He originated eleven U.S. patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall University and San Jose State University. - WilliamE.Rhodes，III自2020年4月起担任董事会成员。在此之前，Rhodes先生自Curetis N.V.于2015年首次公开募股以来一直担任其监事会主席，直到2020年4月1日。罗兹先生是一位梦百合执行官，在梦百合行业拥有30多年的经验。在碧迪医疗器械有限公司的14年职业生涯中（BD，1998年至2012年），Rhodes先生担任过多个高级领导职位，包括BD Biosciences的全球总裁（2009年至2011年），BD的收入超过10亿美元。他也曾担任BD公司的执行官，负责BD&8217；s公司的所有业务的公司战略和并购职能。此外，他还创立了BD Ventures，这是Becton，Dickinson and Co.的风险投资部门。任职Becton Dickinson公司之前，他曾担任强生公司和辉瑞公司公司的高级商业开发职务。Rhodes先生还曾担任The William-James Co.的总裁，并拥有超过20次成功的收购和资产剥离的记录。他曾担任Andor Technologies公司的董事（2013年至2014年），也曾任职Novocell公司、Conticare Medical公司、Vitagen公司、Cellector公司、加州梦百合研究所、Bio公司、圣何塞州立大学研究基金会和硅谷领导小组的董事会。他目前担任Third Day Advisors LLC（2013年以来）、Omega Group plc（2013年以来）、Paramit Corporation LLC（2014年以来）的董事，以及Cayuga Venture Fund的顾问委员会成员（2013年以来）。Rhodes先生在康奈尔大学（Cornell University）担任多个顾问职位，包括担任麦戈文生命科学家庭中心（McGovern Family Center for Life Sciences）的顾问委员会（2013年以来）和康奈尔大学（Cornell）的企业家精神（2015年以来）。他还被任命为康奈尔大学农业和生命科学学院院长&8217；s Council-2016，并担任康奈尔大学Blackstone Launchpad-2016的风险顾问，此外，他还是《临床和转化医学》杂志的编辑委员会成员。Rhodes先生拥有Seton Hall University国际商务硕士学位和Cornell University工商管理硕士学位。他创立了11项新颖外用药物的美国专利，并一直担任Cornell University、Seton Hall University和San Jose State University的生命科学、创新技术和并购创业讲师。
- William E. Rhodes, III has served on our Board since April 2020. Prior to that, Mr. Rhodes served as the Chairman of the Supervisory Board of Curetis N.V. since its Initial Public Offering “IPO” in 2015 until April 1 2020. Mr. Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes held several senior leadership positions, including roles as Worldwide President of BD Biosciences (2009-2011), a greater than $1 billion revenue segment of BD. He was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition functions for all of BD’s businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The William-James Co. and has a track record of over 20 successful acquisitions and divestitures. He was director of Andor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen Inc., Cellector Inc. and the California Healthcare Institute, BIO, the San Jose State University Research Foundation and Silicon Valley Leadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), Omega Group plc (since 2013), Paramit Corporation LLC (since 2014), and as a member of the Advisory Board of Cayuga Venture Fund (since 2013). Mr. Rhodes has a number of advisory roles with Cornell University, including serving on the Advisory Councils of the McGovern Family Center for Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He also was appointed to the Cornell College of Agriculture and Life Sciences Dean’s Council -2016 and served as a Venture Consultant for Cornell’s Blackstone Launchpad -2016 Moreover, he is on the Editorial Board of the journal Clinical and Translational Medicine. Mr. Rhodes holds a Master’s degree in International Business from Seton Hall University and a BSc degree from Cornell University. He originated eleven U.S. patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall University and San Jose State University.
- Mario Crovetto
-
Mario Crovetto自2020年4月起担任董事会成员。他曾担任Curetis N.V.的审计委员会主席（2015年首次公开募股以来），直到2020年4月。Crovetto先生目前担任并购和企业项目的独立顾问，特别是自2011年以来的整合，撤资和融资。从1999年到2011年，他担任Eurand NV（专业制药公司）的首席财务官，并于2007年在纳斯达克上市。从1990年到1999年，他曾担任Recordati公司（制药公司）的多种高级商业职务，包括公司发展副总裁、诊断和首席财务官部门经理。此前，他曾担任Montedison公司（特种化学品）、Digital Equipment Corporation、Mobil and Siar公司（管理咨询）的多种职务。
Mario Crovetto has served on our Board since April 2020. He served as the Chairman of the Audit Committee of Curetis N.V. since its IPO in 2015 until April 2020. Mr. Crovetto is currently serving as an independent advisor on M&A and corporate projects, notably integrations, divestments and financings since 2011. From 1999 to 2011 he was the Chief Financial Officer “CFO” of Eurand NV (Specialty Pharmaceuticals), which he took public to Nasdaq in 2007. From 1990 to 1999 he held various senior business positions at Recordati (Pharmaceuticals), including VP of Corporate Development, Division Manager of Diagnostics and Chief Financial Officer. Prior to that, he held various positions at Montedison (Specialty Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting). - Mario Crovetto自2020年4月起担任董事会成员。他曾担任Curetis N.V.的审计委员会主席（2015年首次公开募股以来），直到2020年4月。Crovetto先生目前担任并购和企业项目的独立顾问，特别是自2011年以来的整合，撤资和融资。从1999年到2011年，他担任Eurand NV（专业制药公司）的首席财务官，并于2007年在纳斯达克上市。从1990年到1999年，他曾担任Recordati公司（制药公司）的多种高级商业职务，包括公司发展副总裁、诊断和首席财务官部门经理。此前，他曾担任Montedison公司（特种化学品）、Digital Equipment Corporation、Mobil and Siar公司（管理咨询）的多种职务。
- Mario Crovetto has served on our Board since April 2020. He served as the Chairman of the Audit Committee of Curetis N.V. since its IPO in 2015 until April 2020. Mr. Crovetto is currently serving as an independent advisor on M&A and corporate projects, notably integrations, divestments and financings since 2011. From 1999 to 2011 he was the Chief Financial Officer “CFO” of Eurand NV (Specialty Pharmaceuticals), which he took public to Nasdaq in 2007. From 1990 to 1999 he held various senior business positions at Recordati (Pharmaceuticals), including VP of Corporate Development, Division Manager of Diagnostics and Chief Financial Officer. Prior to that, he held various positions at Montedison (Specialty Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting).
- Oliver Schacht
-
Oliver Schacht是分子诊断行业的公司财务专业人士和专家，自2020年4月起担任我们的首席执行官兼董事。他曾担任Curetis N.V.的首席执行官（2011年4月至2020年4月），此前曾担任Curetis AG的监事会成员（2010年中期至2011年第一季度末）。他曾担任EpiGenomics AG Berlin，Germany的联合创始人兼首席财务官，以及EpiGenomics Inc.（美国西雅图）的首席执行官。Schacht先生在制定和实施商业战略和融资措施（包括两次首次公开募股），以及在企业融资、并购交易和联盟谈判方面有着丰富的经验。任职EpiGenomics AG期间（1999年至2011年），他曾领导柏林总部的所有中心业务职能，包括公司财务、投资者关系、公关、营销和业务发展。Schacht先生还在Bio Deutschland E.V.的董事会任职，担任总裁，之前担任财务主管。Schacht先生于1994年在罗特林根和伦敦的欧洲商学院（European School of Business）获得欧洲工商管理文凭，并在剑桥大学（英国）获得硕士学位和博士学位。1995年至1999年在Mercer Management Consulting（现Oliver Wyman）任职期间，他从事制药、生物技术和其他行业的并购、增长战略和重组项目。他曾共同创立欧洲和美国生物技术、IT和教育领域的几个初创公司。
Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry who has served as our CEO and Director since April 2020. In addition, as of August 21 2021 upon the departure of Timothy C. Dec, Mr. Schacht is serving as the Acting Chief Financial Officer of the Company. He served as CEO of Curetis N.V. from April 2011 until April 2020 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 until the end of the first quarter of 2011. He was a co-founder and CFO of Epigenomics AG Berlin, Germany and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two initial public offerings), as well as in corporate finance, M&A transactions and alliance negotiations. During his time at Epigenomics AG (1999-2011), he headed all central business functions, including corporate finance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht also serves as Vice Chairman of the ICBA and on the board of BIO Deutschland e.V. as President and previously as treasurer. Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999 he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the United States. - Oliver Schacht是分子诊断行业的公司财务专业人士和专家，自2020年4月起担任我们的首席执行官兼董事。他曾担任Curetis N.V.的首席执行官（2011年4月至2020年4月），此前曾担任Curetis AG的监事会成员（2010年中期至2011年第一季度末）。他曾担任EpiGenomics AG Berlin，Germany的联合创始人兼首席财务官，以及EpiGenomics Inc.（美国西雅图）的首席执行官。Schacht先生在制定和实施商业战略和融资措施（包括两次首次公开募股），以及在企业融资、并购交易和联盟谈判方面有着丰富的经验。任职EpiGenomics AG期间（1999年至2011年），他曾领导柏林总部的所有中心业务职能，包括公司财务、投资者关系、公关、营销和业务发展。Schacht先生还在Bio Deutschland E.V.的董事会任职，担任总裁，之前担任财务主管。Schacht先生于1994年在罗特林根和伦敦的欧洲商学院（European School of Business）获得欧洲工商管理文凭，并在剑桥大学（英国）获得硕士学位和博士学位。1995年至1999年在Mercer Management Consulting（现Oliver Wyman）任职期间，他从事制药、生物技术和其他行业的并购、增长战略和重组项目。他曾共同创立欧洲和美国生物技术、IT和教育领域的几个初创公司。
- Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry who has served as our CEO and Director since April 2020. In addition, as of August 21 2021 upon the departure of Timothy C. Dec, Mr. Schacht is serving as the Acting Chief Financial Officer of the Company. He served as CEO of Curetis N.V. from April 2011 until April 2020 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 until the end of the first quarter of 2011. He was a co-founder and CFO of Epigenomics AG Berlin, Germany and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two initial public offerings), as well as in corporate finance, M&A transactions and alliance negotiations. During his time at Epigenomics AG (1999-2011), he headed all central business functions, including corporate finance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht also serves as Vice Chairman of the ICBA and on the board of BIO Deutschland e.V. as President and previously as treasurer. Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999 he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the United States.
- Prabhavathi Fernandes
-
Prabhavathi Fernandes，（哲学博士）是公司的创始人之一。自公司2005年11月成立以来，Fernandes博士在公司担任总裁、首席执行官和董事。2003年至2005年，她担任包括DarPharma, Inc.在内的一些私营公司的总裁和首席执行官。2000年，她在Ricerca Biosciences 担任总裁和首席执行官。1998年至2000年，她在Small Molecule Therapeutics担任总裁和首席执行官。1988年至1998年，她担任Bristol-Myers Squibb Company 的新药开发部门的副总裁。1987年至1988年，她是Squibb Pharmaceutical Research Institute 的高级主管。1983年至1987年，她担任 Abbott Laboratories 的高级项目负责人。1980年至1983年，她担任Squibb Institute for Medical Research的高级微生物分析师。2004年，她在Optimer Pharmaceuticals, Inc的咨询委员会任职。2004年至2008年，她在GPC Biotech AG的监事会任职。2003年至2004年，Fernandes博士在国家过敏与感染性疾病研究所的生物预防产品开发工作部工作。1991年至1995年，她在美国国会小组的抗药性细菌影响评估组和美国微生物学会的抗菌素耐药性顾问小组工作。她在印度邦加罗尔大学获得了植物学、动物学和化学学士学位，在印度的基督教医学院获得了微生物学硕士学位，在宾夕法尼亚州费城的托马斯杰斐逊大学获得了微生物学（哲学）博士学位。
Prabhavathi Fernandes has served on our Board since April 2020. Previously, she served as a member of the Curetis N.V. Supervisory Board from 2016 until April 1 2020 and from 2006 until her retirement in 2016 served as President, Chief Executive Officer “CEO” and director of Cempra Inc., a company she founded. She has more than 40 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb in 1997 she founded and led four biotechnology and CRO companies as President, CEO and director, including Cempra, DarPharma, Ricerca and Small Molecule Therapeutics. During her years in the pharmaceutical industry, she was directly involved with the development of 4 antibiotics for human use and 2 for animal/agricultural use. She is currently the Chairperson of National Biodefense Science Board (NBSB), the Chairperson of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership (GARDP), a DNDi/WHO initiative, a member of the Clinical Antibacterial Pipeline advisory group for the WHO and member of the ACTIV NIH working group for therapeutics and vaccines for COVID-19. She is on the Board of Directors of Aelin Therapeutics and Ocugen and advises several other companies. She has authored numerous publications and several reviews, book chapters and currently serves as a section editor for Journal of Antibiotics. She obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, and received her Ph.D. in Microbiology from Thomas Jefferson University in Philadelphia. - Prabhavathi Fernandes，（哲学博士）是公司的创始人之一。自公司2005年11月成立以来，Fernandes博士在公司担任总裁、首席执行官和董事。2003年至2005年，她担任包括DarPharma, Inc.在内的一些私营公司的总裁和首席执行官。2000年，她在Ricerca Biosciences 担任总裁和首席执行官。1998年至2000年，她在Small Molecule Therapeutics担任总裁和首席执行官。1988年至1998年，她担任Bristol-Myers Squibb Company 的新药开发部门的副总裁。1987年至1988年，她是Squibb Pharmaceutical Research Institute 的高级主管。1983年至1987年，她担任 Abbott Laboratories 的高级项目负责人。1980年至1983年，她担任Squibb Institute for Medical Research的高级微生物分析师。2004年，她在Optimer Pharmaceuticals, Inc的咨询委员会任职。2004年至2008年，她在GPC Biotech AG的监事会任职。2003年至2004年，Fernandes博士在国家过敏与感染性疾病研究所的生物预防产品开发工作部工作。1991年至1995年，她在美国国会小组的抗药性细菌影响评估组和美国微生物学会的抗菌素耐药性顾问小组工作。她在印度邦加罗尔大学获得了植物学、动物学和化学学士学位，在印度的基督教医学院获得了微生物学硕士学位，在宾夕法尼亚州费城的托马斯杰斐逊大学获得了微生物学（哲学）博士学位。
- Prabhavathi Fernandes has served on our Board since April 2020. Previously, she served as a member of the Curetis N.V. Supervisory Board from 2016 until April 1 2020 and from 2006 until her retirement in 2016 served as President, Chief Executive Officer “CEO” and director of Cempra Inc., a company she founded. She has more than 40 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb in 1997 she founded and led four biotechnology and CRO companies as President, CEO and director, including Cempra, DarPharma, Ricerca and Small Molecule Therapeutics. During her years in the pharmaceutical industry, she was directly involved with the development of 4 antibiotics for human use and 2 for animal/agricultural use. She is currently the Chairperson of National Biodefense Science Board (NBSB), the Chairperson of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership (GARDP), a DNDi/WHO initiative, a member of the Clinical Antibacterial Pipeline advisory group for the WHO and member of the ACTIV NIH working group for therapeutics and vaccines for COVID-19. She is on the Board of Directors of Aelin Therapeutics and Ocugen and advises several other companies. She has authored numerous publications and several reviews, book chapters and currently serves as a section editor for Journal of Antibiotics. She obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, and received her Ph.D. in Microbiology from Thomas Jefferson University in Philadelphia.
高管简历
中英对照 | 中文 | 英文- Oliver Schacht
Oliver Schacht是分子诊断行业的公司财务专业人士和专家，自2020年4月起担任我们的首席执行官兼董事。他曾担任Curetis N.V.的首席执行官（2011年4月至2020年4月），此前曾担任Curetis AG的监事会成员（2010年中期至2011年第一季度末）。他曾担任EpiGenomics AG Berlin，Germany的联合创始人兼首席财务官，以及EpiGenomics Inc.（美国西雅图）的首席执行官。Schacht先生在制定和实施商业战略和融资措施（包括两次首次公开募股），以及在企业融资、并购交易和联盟谈判方面有着丰富的经验。任职EpiGenomics AG期间（1999年至2011年），他曾领导柏林总部的所有中心业务职能，包括公司财务、投资者关系、公关、营销和业务发展。Schacht先生还在Bio Deutschland E.V.的董事会任职，担任总裁，之前担任财务主管。Schacht先生于1994年在罗特林根和伦敦的欧洲商学院（European School of Business）获得欧洲工商管理文凭，并在剑桥大学（英国）获得硕士学位和博士学位。1995年至1999年在Mercer Management Consulting（现Oliver Wyman）任职期间，他从事制药、生物技术和其他行业的并购、增长战略和重组项目。他曾共同创立欧洲和美国生物技术、IT和教育领域的几个初创公司。
Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry who has served as our CEO and Director since April 2020. In addition, as of August 21 2021 upon the departure of Timothy C. Dec, Mr. Schacht is serving as the Acting Chief Financial Officer of the Company. He served as CEO of Curetis N.V. from April 2011 until April 2020 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 until the end of the first quarter of 2011. He was a co-founder and CFO of Epigenomics AG Berlin, Germany and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two initial public offerings), as well as in corporate finance, M&A transactions and alliance negotiations. During his time at Epigenomics AG (1999-2011), he headed all central business functions, including corporate finance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht also serves as Vice Chairman of the ICBA and on the board of BIO Deutschland e.V. as President and previously as treasurer. Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999 he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the United States.- Oliver Schacht是分子诊断行业的公司财务专业人士和专家，自2020年4月起担任我们的首席执行官兼董事。他曾担任Curetis N.V.的首席执行官（2011年4月至2020年4月），此前曾担任Curetis AG的监事会成员（2010年中期至2011年第一季度末）。他曾担任EpiGenomics AG Berlin，Germany的联合创始人兼首席财务官，以及EpiGenomics Inc.（美国西雅图）的首席执行官。Schacht先生在制定和实施商业战略和融资措施（包括两次首次公开募股），以及在企业融资、并购交易和联盟谈判方面有着丰富的经验。任职EpiGenomics AG期间（1999年至2011年），他曾领导柏林总部的所有中心业务职能，包括公司财务、投资者关系、公关、营销和业务发展。Schacht先生还在Bio Deutschland E.V.的董事会任职，担任总裁，之前担任财务主管。Schacht先生于1994年在罗特林根和伦敦的欧洲商学院（European School of Business）获得欧洲工商管理文凭，并在剑桥大学（英国）获得硕士学位和博士学位。1995年至1999年在Mercer Management Consulting（现Oliver Wyman）任职期间，他从事制药、生物技术和其他行业的并购、增长战略和重组项目。他曾共同创立欧洲和美国生物技术、IT和教育领域的几个初创公司。
- Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry who has served as our CEO and Director since April 2020. In addition, as of August 21 2021 upon the departure of Timothy C. Dec, Mr. Schacht is serving as the Acting Chief Financial Officer of the Company. He served as CEO of Curetis N.V. from April 2011 until April 2020 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 until the end of the first quarter of 2011. He was a co-founder and CFO of Epigenomics AG Berlin, Germany and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two initial public offerings), as well as in corporate finance, M&A transactions and alliance negotiations. During his time at Epigenomics AG (1999-2011), he headed all central business functions, including corporate finance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht also serves as Vice Chairman of the ICBA and on the board of BIO Deutschland e.V. as President and previously as treasurer. Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999 he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the United States.
- Johannes Bacher
Johannes Bacher自2020年4月起担任我们的首席运营官。在此之前，他管理Curetis公司在工程、软件、体外诊断开发、创新和技术、知识产权和临床试验操作方面的所有研究与开发职能。自2007年共同创立Curetis公司以来，他一直担任Curetis公司的董事总经理兼运营董事（2008年以来），以及首席运营官（Curetis公司（2012年以来）、Curetis GmbH公司（2015年以来）。Bacher先生拥有德国斯图加特大学（University of Stuttgart）的电气工程学位，此前曾在惠普公司（Hewlett-Packard）、安捷伦科技公司（Agilent Technologies）和飞利浦医疗系统公司（Philips Medical Systems）任职。
Johannes Bacher has served as our Chief Operating Officer since April 2020. Prior to that, he managed for Curetis all research and development functions in engineering, software, in vitro diagnostics development, innovation and technology, intellectual property and clinical trial operations. Since co-founding Curetis in 2007 he has continuously served as Managing Director and Director Operations Curetis AG, since 2008 and Chief Operations Officer (Curetis AG, since 2012; Curetis GmbH and publicly listed Curetis N.V. since 2015). Mr. Bacher has a degree in Electrical Engineering from the University of Stuttgart, Germany, and has previously held positions with Hewlett-Packard, Agilent Technologies and Philips Medical Systems.- Johannes Bacher自2020年4月起担任我们的首席运营官。在此之前，他管理Curetis公司在工程、软件、体外诊断开发、创新和技术、知识产权和临床试验操作方面的所有研究与开发职能。自2007年共同创立Curetis公司以来，他一直担任Curetis公司的董事总经理兼运营董事（2008年以来），以及首席运营官（Curetis公司（2012年以来）、Curetis GmbH公司（2015年以来）。Bacher先生拥有德国斯图加特大学（University of Stuttgart）的电气工程学位，此前曾在惠普公司（Hewlett-Packard）、安捷伦科技公司（Agilent Technologies）和飞利浦医疗系统公司（Philips Medical Systems）任职。
- Johannes Bacher has served as our Chief Operating Officer since April 2020. Prior to that, he managed for Curetis all research and development functions in engineering, software, in vitro diagnostics development, innovation and technology, intellectual property and clinical trial operations. Since co-founding Curetis in 2007 he has continuously served as Managing Director and Director Operations Curetis AG, since 2008 and Chief Operations Officer (Curetis AG, since 2012; Curetis GmbH and publicly listed Curetis N.V. since 2015). Mr. Bacher has a degree in Electrical Engineering from the University of Stuttgart, Germany, and has previously held positions with Hewlett-Packard, Agilent Technologies and Philips Medical Systems.